-THC by functionally activating CB receptors, and these are the endocannabinoids whose biological activity has been best characterized to date (Di Marzo, 2009; Maccarrone et al., 2010) .
CB 1 receptor is the most abundant G protein-coupled receptor (GPCR) in the brain (Howlett et al., 2010) . Together with its endogenous agonists (AEA, 2-AG, and other congeners), CB 1 belongs to an ancient neurosignaling system that plays important control functions within the central nervous system (Katona and Freund, 2008) . Alterations in this so-called "endocannabinoid system" have been extensively investigated in a wide range of neurodegenerative and neuroinflammatory disorders, spanning from Alzheimer's disease, Parkinson's disease and Huntington's disease, to amyotrophic lateral sclerosis and multiple sclerosis (Bisogno and Di Marzo, 2010) . For this reason, research on the therapeutic potential of drugs modulating the endocannabinoid system is very intense (Di Marzo, 2009 ). More recently, it has become evident the involvement of membrane lipids, especially cholesterol and glycosphingolipids, in regulating the function of GPCRs like β 2 -adrenergic and serotonin 1A receptors, as well as of several other membrane-associated proteins like caveolins (Pontier et al., 2008; Prinetti et al., 2009; Paila et al., 2010; Shrivastava et al., 2010) . Also a role for membrane cholesterol in the functional regulation of CB 1 has been well-documented (for an updated review see Dainese et al., 2010) . Acute cholesterol depletion by methyl-β-cyclodextrin has been shown to double CB 1 -dependent signaling via adenylyl cyclase and mitogenactivated protein kinases in neuronal cells (Bari et al., 2005a,b) . Conversely, it has been reported that in the same cells CB 1 -dependent binding and signaling was significantly reduced by cholesterol enrichment (Bari et al., 2005a (Bari et al., ,b, 2006 . Notably, the CB 2 receptor that is structurally and functionally related to CB 1 is completely insensitive to the modulation of membrane cholesterol content (Bari et al., 2006) , and does not reside in cholesterolrich microdomains like lipid rafts (Bari et al., 2006; Rimmerman et al., 2008) . As yet, the molecular basis for the different response of these two receptor subtypes to cholesterol remains unclear, although its impact on the therapeutic exploitation of CB 1 -dependent endocannabinoid signaling versus that dependent on CB 2 could be immense.
Here, I would like to comment that subtle, yet specific, differences might underpin the differential sensitivity of CB 1 and CB 2 to membrane cholesterol, possibly explaining the apparent redundancy of having two largely overlapping receptor subtypes that are activated by similar compounds (endocannabinoids) and trigger similar transduction pathways: (i) inhibition of adenylyl cyclase, (ii) regulation of ionic currents (e.g., inhibition of voltage-gated L, N, and P/Q-type Ca 2+ channels, and activation of K + channels), and (iii) activation of focal adhesion kinase, mitogen-activated protein kinase, and cytosolic phospholipase A 2 (Di Marzo, 2009; Maccarrone et al., 2010) .
In general, cholesterol may act on the conformation of a membrane receptor by indirectly altering the physicochemical properties of the bilayer, or by directly interacting with the receptor itself. Although a unique conserved structural determinant for protein interaction with cholesterol has not yet been identified, a well-known motif is the cholesterol interaction/recognition amino acid sequence (Epand, 2006) . This motif has been demonstrated in caveolin-1, peripheraltype benzodiazepine receptor (Li and Papadopoulos, 1998; Jamin et al., 2005) , and in other proteins targeted to lipid rafts (Xie et al., 2010) . Interestingly, by sequence alignment of human CB 1 and CB 2 we have recently identified the presence of CRAC in the last 11 amino acids of the transmembrane helix 7 of both CB 1 and CB 2 (Oddi et al., 2011) . In particular, we found that in the highly conserved CRAC region (82% amino acid identity), CB 1 differs from CB 2 for one residue only: lysine 402 of CB 1 (Figure 1 ) corresponds to glycine 304 in CB 2 (Oddi et al., 2011) . We also found that the CB 1 (K402G) mutant where the CRAC sequence of CB 1 was converted into that of CB 2 had a reduced propensity to reside in cholesterol-rich membrane regions, and lost its sensitivity to membrane cholesterol enrichment (Oddi et al., 2011) . Therefore, one residue in complex proteins like GPCRs can be enough to direct their interaction with membrane lipids, thus affecting signal transduction thereof.
Different non-mutually exclusive mechanisms could be proposed to explain the differential sensitivity of CB 1 and CB 2 to membrane cholesterol: (i) compartmentalization in cholesterol-rich microdomains; (ii) caveolar endocytosis; (iii) cholesteroldependent receptor dimerization; (iv) hydrophobic mismatch; (v) modulation of the rate of endocannabinoid movement within the membrane . Additionally, it is possible that the different effect of membrane cholesterol on CB 1 and CB 2 is due to subtle differences in the domain(s) that interact(s) with the surrounding (non-annular) lipids, by analogy lipids. As a consequence, the membrane environment might play a role in receptordependent signaling, with a potential impact on several neurotransmission pathways, as well as several neurodegenerative/neuroinflammatory diseases where CB 1 is known to play a role. More in general, it should be recalled that CB 1 -dependent signaling impacts fundamental processes as different as immune response, energy homeostasis, reproduction, and skin differentiation (Di Marzo, 2009; Maccarrone et al., 2010) , thus it can be anticipated that cholesteroldependent regulation of CB 1 can have a physiological relevance well-beyond the central nervous system.
In conclusion, membrane environment seems to be critical for the regulation of signal transduction pathways triggered by G with other GPCRs . Additionally, other lipid-interacting residues might direct the interaction of CB 1 with the surrounding membrane lipids, e.g., cysteine 415 in its C-terminal (Figure 1) , that could be the target of palmitoylation . The latter reversible post-translational modification can be used by cells to regulate CB 1 targeting to cholesterol-rich subdomains of the membrane, thus influencing its interaction with coupled G proteins.
I believe that the comparison between CB 1 and CB 2 might represent an interesting paradigm that goes well-beyond endocannabinoid signaling. In fact, the modulation of CB 1 by cholesterol might disclose a novel ligand-receptor interaction, where a third player comes into the game: membrane . The three residues (V392, Y397, K402) that form the CRAC sequence are represented as yellow spheres, sized to the Van der Waals radii; these residues belong to the transmembrane helix 7 of CB 1 . Recently, we have generated a mutant where a lysine residue (K402) was substituted by glycine, thus converting the CRAC sequence of CB 1 into that of CB 2 (Oddi et al., 2011) . Additionally, the C-terminal component of CB 1 , i.e., the intracellular juxtamembrane α-helix 8, contains a cysteine residue (C415, in green) that could be constitutively palmitoylated. See text for details. The model was kindly provided by Dr. Enrico Dainese (University of Teramo, Italy).
protein-coupled receptors like CB 1 . Despite the three-dimensional complexity of these proteins, we learn from the comparison of CB 1 with CB 2 that just one amino acid residue can direct receptor functioning, calling for attention on the plasma membrane as a key-player in ligand recognition on the cell surface.
